StatSure Diagnostic Systems, Inc. Announces First Quarter Revenues and Management Changes

  
    
  
  
    
      StatSure Diagnostic Systems, Inc. (OTCBB: “SSUR”) 
      today announced its financial results for the three months ended March 
      31, 2008. The increase in revenue for the three months in 2008 consists 
      of greater sales of our saliva collectors and an increase in license 
      fees from the Company’s various license 
      agreements with ChemBio and Inverness.
    
    
      
        
        
        
           
        
        
           
        
        
           
        
        
        
      
      
        
        
        
        
        
        
        
        
        
          Three Months Ended March 31,
        
      
      
        
        
        
        
        
        
        
        
        
          2008
        
        
           
        
        
          2007
        
      
      
        
          Product Sales
        
        
        
        
        
        
        
        
          $
        
        
          224,370
        
        
        
        
          $
        
        
          142,862
        
      
      
        
          Royalty and Other Income
        
        
        
        
        
        
        
        
        
        
          35,800
        
        
        
        
        
        
          10,986
        
      
      
        
          Selling, general and administrative expenses
        
        
        
        
        
        
        
        
        
        
          244,579
        
        
        
        
        
        
          495,604
        
      
      
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
           
        
      
    
    
      Additionally, the Company announced that effective July 1, 2008, Mr. 
      Steve M. Peltzman, Chairman of the Board and Chief Executive Officer, 
      and Mr. D. Bruce Pattison, President, Chief Operating Officer and 
      Director, have resigned. Messrs Peltzman and Pattison, have indicated 
      that they will enter into Consulting Agreements with StatSure. In 
      addition, Mr. Richard Woodrich has resigned as Director. Concurrently, 
      the Board elected Mr. Moishe Bodner, currently Vice President of the 
      Company, as Chief Executive Officer and Director, and Mr. Leo Ehrlich, 
      the current Chief Financial Officer and Director, was elected as the 
      President, Chief Operating Officer effective July 1, 2008.
    
    
      The incoming Chief Executive Officer noted that the Company accepted the 
      resignations of Mr. Peltzman and Mr. Pattison with regret, and thanked 
      them for their services. As Mr. Bodner pointed out, “Their 
      commercial leadership and expertise with respect to strategic partnering 
      and regulatory affairs raised StatSure to a new level in consummating 
      the transactions with Inverness and ChemBio, as well as other 
      transactions which will allow us to increase the revenues and margins 
      from our existing products and technology. While they have reduced their 
      time commitments to the Company, StatSure will be able to avail itself 
      of their knowledge and expertise as consultants to the Company.”
    
    
      The Company also announced that it had been granted a patent on one of 
      its key technologies in Brazil.
    
    
      About StatSure
    
    
      StatSure Diagnostic Systems, Inc. (OTC Bulletin Board: SSUR) is engaged 
      in the development, manufacture and marketing of rapid immunoassay tests 
      for the detection of sexually transmitted and other infectious diseases; 
      in addition, the Company has developed and is marketing a product line 
      of patented, oral- fluid collection devices. The Company's proprietary 
      platforms provide significant customer benefits and competitive 
      advantages as compared to similar products that are currently available. 
      Improved accuracy, operator convenience, and reduced risk of infection 
      from collecting and handling specimens, have been engineered into SDS 
      products. All of the company's diagnostic tests are based on the same 
      easy-to-use technology platform, thus facilitating the development of 
      future products. Certain of these products are sold in the United States 
      as well as internationally to various distributors for use in clinical 
      laboratories, hospitals, clinics, community-based organizations and 
      other public health organizations.
    
    
      Please visit our website at http://www.StatSure.com.
    
    
      Forward-Looking Statements
    
    
      Statements contained herein that are not historical facts are forward- 
      looking statements within the meaning of the Securities Act of 1933, as 
      amended. Those statements include statements regarding the intent, 
      belief or current expectations of the company and its management. Such 
      statements reflect management's current views, are based on certain 
      assumptions and involve risks and uncertainties. Actual results, events, 
      or performance may differ materially from the above forward-looking 
      statements due to a number of important factors, and will be dependent 
      upon a variety of factors, including, but not limited to, the Company's 
      ability to obtain additional financing and the demand for the Company's 
      products. The Company undertakes no obligation to publicly update these 
      forward-looking statements to reflect events or circumstances that occur 
      after the date hereof or to reflect any change in the Company's 
      expectations with regard to these forward-looking statements or the 
      occurrence of unanticipated events. Factors that may impact the 
      Company's success are more fully disclosed in the Company's most recent 
      public filings with the U.S. Securities and Exchange Commission ("SEC").
    
    
      StatSure Diagnostic Systems, Inc.
    
    
      http://www.StatSure.com